Evidence map›Paper›PMID 41915133›Full record

ReviewEJNMMI radiopharmacy and chemistry2026

Lung perfusion imaging in nuclear medicine with

Hassan Zareian, Mehrnaz Mardazad, Mahshid Kiani, Nafise Pourshafagh, Fateme Karimi, Mehdi Shafee Ardestani

Abstract readReview
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hassan ZareianDepartment of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran. hassanzareian15@gmail.com.ORCID http://orcid.org/0009-0002-1557-5010
Mehrnaz MardazadNuclear Medicine Technologist, Iran University of Medical Sciences, Tehran, Iran.
Mahshid KianiDepartment of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Nafise PourshafaghDepartment of Medical Physics, Iran University of Medical Sciences, Tehran, Iran.
Fateme KarimiDepartment of Nuclear Medicine Technology, Faculty of Paramedicine, Babol University of Medical Sciences, Mazandaran, Iran.
Mehdi Shafee ArdestaniDepartment of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTechnetium-99 m-labeled macroaggregated albumin ([⁹⁹ᵐTc]Tc-MAA) is the standard agent for lung perfusion imaging in pulmonary embolism (PE). Limitations related to particle consistency, preparation procedures, and blood-derived origin have prompted the development of alternative non-blood-derived tracers. MAIN BODY: A narrative review of studies up to August 2025 was performed. Candidate radiopharmaceuticals were evaluated for pulmonary localization, physicochemical properties, quality control characteristics, radiopharmacy practicality, kit-based preparation, and preclinical or clinical validation. Biodegradable microspheres, synthetic colloids, starch-based microparticles, and small-molecule complexes demonstrated promising lung uptake. Most tracers, however, lacked standardized preparation, kit compatibility, or validation in PE-relevant models. Starch-based microparticles emerged as the most translationally promising, showing practical workflow and favorable biodistribution.

conclusionNo non-blood-derived ⁹⁹ᵐTc tracer currently matches [⁹⁹ᵐTc]Tc-MAA for routine lung perfusion imaging. Future development requires standardized, pharmacopeia-aligned tracers, head-to-head comparisons, and systematic evaluation in early-phase clinical trials.

Indexed as

ChitosanLung perfusion imagingMacroaggregated albumin (MAA)RadiopharmaceuticalsStarch microparticlesTechnetium-99m (⁹⁹ᵐTc)

Identifiers

PMID41915133
PMCPMC13161414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.